脂质代谢与乳腺癌曲妥珠单抗耐药性机制的相关性研究

doi:10.11904/j.issn.1002-3070.2023.02.011

Abstract

Abstract: The emergence of trastuzumab has greatly improved the prognosis of patients with HER2-positive breast cancer,but some patients still develop primary or secondary trastuzumab resistance during treatment.In recent years,the drug resistance mechanism of trastuzumab has attracted more and more attention,but the drug resistance phenomenon has not been fully elucidated.Lipid metabolism,as a basic physiological activity to maintain cell survival,is closely related to the resistance of HER2-positive breast cancer cells to targeted therapy,and is expected to become a new target for the treatment of trastuzumab resistance.This article reviews the relationship between lipid metabolism and the mechanism of trastuzumab resistance.

Key words: Lipid metabolism, HER2 positive breast cancer, Drug resistance

CLC Number:

R737.9

FENG Chengtian, HUANG Furong, JIANG Yongdong. Research progress of lipid metabolism on the mechanism of drug resistance to trastuzumab therapy in breast cancer[J]. Journal of Practical Oncology, 2023, 37(2): 155-159.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2023.02.011

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2023/V37/I2/155

References

1 Yan H,Xiao H,Zhu J,et al.Association between the HER2 protein expression level and the efficacy of neoadjuvant chemotherapy in HER2-positive breast cancer[J].Cancer Manag Res,2020,12:12715-12722.
2 Fernandez-nogueira P,Mancino M,Fuster G,et al.Tumor-associated fibroblasts promote HER2-targeted therapy resistance through FGFR2 activation[J].Clin Cancer Res,2020,26(6):1432-1448.
3 王星涵,吕雅蕾.曲妥珠单抗耐药机制及HER2阳性乳腺癌耐药后的治疗策略[J].实用肿瘤学杂志,2022,36(5):445-451.
4 Huang C,Freter C.Lipid metabolism,apoptosis and cancer therapy[J].Int J Mol Sci,2015,16(1):924-949.
5 Bian X,Liu R,Meng Y,et al.Lipid metabolism and cancer[J].J Exp Med,2021,218(1):e20201606.
6 Cao Y.Adipocyte and lipid metabolism in cancer drug resistance[J].J Clin Invest,2019,129(8):3006-3017.
7 Feng WW,Wilkins O,Bang S,et al.CD36-mediated metabolic rewiring of breast cancer cells promotes resistance to HER2-targeted therapies[J].Cell Rep,2019,29(11):3405-3420.
8 Ligorio F,Pellegrini I,Castagnoli L,et al.Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer[J].Cancer Lett,2021,511:77-87.
9 Han J,Qu H,Han M,et al.MSC-induced lncRNA AGAP2-AS1 promotes stemness and trastuzumab resistance through regulating CPT1 expression and fatty acid oxidation in breast cancer[J].Oncogene,2021,40(4):833-847.
10 Jung YY,Kim HM,Koo JS.Expression of lipid metabolism-related proteins in metastatic breast cancer[J].PLoS One,2015,10(9):e0137204.
11 Vazquez-martin A,Colomer R,Brunet J,et al.Pharmacological blockade of fatty acid synthase(FASN)reverses acquired autoresistance to trastuzumab(Herceptin^im)by transcriptionally inhibiting′HER2 super-expression′occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells[J].Int J Oncol,2007,31(4):769-776.
12 Ravacci GR,Brentani MM,Tortelli TC,et al.Docosahexaenoic acid modulates a HER2-associated lipogenic phenotype,induces apoptosis,and increases Trastuzumab action in HER2-overexpressing breast carcinoma cells[J].Biomed Res Int,2015,2015:838652.
13 Menendez JA.Fine-tuning the lipogenic/lipolytic balance to optimize the metabolic requirements of cancer cell growth:molecular mechanisms and therapeutic perspectives[J].Biochim Biophys Acta,2010,1801(3):381-391.
14 Mao Y,Zhang Y,Qu Q,et al.Cancer-associated fibroblasts induce trastuzumab resistance in HER2 positive breast cancer cells[J].Mol Biosyst,2015,11(4):1029-1040.
15 Griner SE,Wang KJ,Joshi JP,et al.Mechanisms of adipocytokine-mediated Trastuzumab resistance in HER2-positive breast cancer cell lines[J].Curr Pharmacogenomics Person Med,2013,11(1):31-41.
16 Duong MN,Cleret A,MAtera EL,et al.Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity[J].Breast Cancer Res,2015,17(1):57.
17 ROdriguez-barrueco R,Yu J,SAucedo-cuevas LP,et al.Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers[J].Genes Dev,2015,29(15):1631-1648.
18 Liu S,Lee J S,Jie C,et al.HER2 overexpression triggers an IL1alpha proinflammatory circuit to drive tumorigenesis and promote chemotherapy resistance[J].Cancer Res,2018,78(8):2040-2051.
19 Manore SG,Doheny DL,Wong GL,et al.IL-6/JAK/STAT3 signaling in breast cancer metastasis:biology and treatment[J].Front Oncol,2022,12:866014.
20 Korkaya H,Kim GI,Davis A,et al.Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population[J].Mol Cell,2012,47(4):570-584.
21 Felcher CM,Bogni ES,Kordon EC.IL-6 cytokine family:A putative target for breast cancer prevention and treatment[J].Int J Mol Sci,2022,23(3).
22 Mercogliano MF,Bruni S,ElizaLDE PV,et al.Tumor necrosis factor alpha blockade:an opportunity to tackle breast cancer[J].Front Oncol,2020,10:584.
23 Hermawan A,Putri H.Integrative bioinformatics analysis reveals potential target genes and TNFα signaling inhibition by brazilin in metastatic breast cancer cells[J].Asian Pac J Cancer Prev,2020,21(9):2751-2762.
24 Song PN,Mansur A,Dugger KJ,et al.CD4 T-cell immune stimulation of HER2+ breast cancer cells alters response to trastuzumab in vitro[J].Cancer Cell Int,2020,20(1):544.
25 Mercogliano MF,DE martino M,VenTurutti L,et al.TNFα-induced mucin 4 expression elicits Trastuzumab resistance in HER2-positive breast cancer[J].Clin Cancer Res,2017,23(3):636-648.
26 Rio M C,Dali-youcef N,Tomasetto C.Local adipocyte cancer cell paracrine loop:can“sick fat”be more detrimental?[J].Horm Mol Biol Clin Investig,2015,21(1):43-56.
27 Bielczyk-maczynska E.White adipocyte plasticity in physiology and disease[J].Cells,2019,8(12):1507.
28 Okumura T,Ohuchida K,Kibe S,et al.Adipose tissue-derived stromal cells are sources of cancer-associated fibroblasts and enhance tumor progression by dense collagen matrix[J].Int J Cancer,2019,144(6):1401-1413.
29 陈都,钱诚.乳腺癌肿瘤微环境中间质细胞介导的化疗耐药性研究进展[J].实用肿瘤学杂志,2020,34(4):382-386.
30 Luque M,Sanz-alvarez M,Santamaria A,et al.Targeted therapy modulates the secretome of cancer-associated fibroblasts to induce resistance in HER2-positive breast cancer[J].Int J Mol Sci,2021,22(24):13297.
31 Zhong H,Davis A,Ouzounova M,et al.A Novel IL6 antibody sensitizes multiple tumor types to chemotherapy including Trastuzumab-resistant tumors[J].Cancer Res,2016,76(2):480-490.

[1]	LI Zhihui, LI Zhigao. Research progress of T-DM1 in treatment of HER2 positive breast cancer [J]. Journal of Practical Oncology, 2022, 36(5): 477-482.
[2]	YU Chengping, CUI Yongkang, LI Linqiang. Research progress of eccDNA in cancer [J]. Journal of Practical Oncology, 2022, 36(3): 255-258.
[3]	WANG Zongwen, LI Xiaodong, ZHU Qiankun, ZENG Shicong, ZHAI Bo. KIF14 in the mechanism of acquired drug resistance in hepatocellular carcinoma SMCC-7721 cells [J]. Journal of Practical Oncology, 2022, 36(1): 14-19.
[4]	JI Lei, JI Daolin, BAO Dongdong, TAN Gang. The latest research progress of long non-coding RNA in sorafenib resistance of hepatocellular carcinoma [J]. Journal of Practical Oncology, 2021, 35(6): 562-567.
[5]	LI Yuying, ZHANG Yue. Research progress of Sirtuins in breast cancer [J]. Journal of Practical Oncology, 2021, 35(3): 277-281.
[6]	GUO Piaoting, ZOU Yang. LncRNA SOX2OT sponge adsorbs miR-34a to promote SOX2 expression and enhance multidrug resistance in colorectal cancer [J]. Journal of Practical Oncology, 2020, 34(5): 398-403.
[7]	LIANG Yongqin, ZHAO Hongwei. Application progress of antiangiogenic drugs in platinum-resistant ovarian cancer [J]. Journal of Practical Oncology, 2020, 34(1): 60-63.
[8]	HUANG Xianbo, SHI Ting, YE Xiujin. Progress in the treatment of acute T lymphoblastic leukemia by targeting PI3K/AKT/mTOR pathway [J]. Journal of Practical Oncology, 2019, 33(5): 451-455.
[9]	SUN Lina, ZHAO Xiaodi, LU Yuanyuan, WANG Xin. Research progress of LncRNA and chemotherapy resistance in gastrointestinal neoplasms [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(5): 448-453.
[10]	ZENG Yulan,LIU Yangyang,LIANG Jinyan,GU Feifei,LIU Li. Advances in drug resistance mechanism of immunological checkpoint inhibitors and post-drug resistant therapeutic strategy [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(4): 353-358.
[11]	HUANG Jian,PANG Hui,SONG Yuhang,CAI Li. The role of microRNA in drug resistance of breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(3): 272-276.
[12]	DUAN Peiwen, ZHAO Miaomiao, WANG Songpo. The recent advances in the research of NF-κB in the development and relevant treatment of the colorectal cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(1): 43-47.
[13]	ZHAO Yu,ZHU Xiaoting,WANG Yinan. The role and mechanisms of ω-3 polyunsaturated fatty acids in inducing cell apoptosis and anti-proliferation in multiple myeloma [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(6): 516-522.
[14]	REN Tingting,XING Ying,MENG Qingwei. Progress in association between autophagy and cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(6): 543-546.
[15]	CHI Shuqi, WANG Hongbo. LncRNAs and drug resistance in tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(2): 150-153.

Research progress of lipid metabolism on the mechanism of drug resistance to trastuzumab therapy in breast cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments